IBL News Details
Product News
- Product News2023/10/31
- Gd-IgA1(Galactose-deficient IgA1) (Autumn Newsletter 2023)
Related Materials
Highlights – Galactose-deficient IgA1 (Gd-IgA1)
Gd-IgA1revel in Serum
We hope this newsletter finds you well. After a summer with record-breaking heat, it is getting cooler everyday here in Japan. This newsletter focus about IgA Nephropathy.
Chronic Kidney Disease (CKD) is a progressive loss in kidney function and it affects 1 in 10 people around the world. Majour causes of CKD are type 2 diabetic nephropathy, polycystic kidney disease and chronic glomerulonephritis. IgA nephropathy (IgAN) is the most common type of primary chronic glomerulonephritis.
Galactose-deficient IgA1 (Gd-IgA1) has been reported as a critical effector molecule in the pathogenesis and progression of IgAN.
Chronic Kidney Disease (CKD) is a progressive loss in kidney function and it affects 1 in 10 people around the world. Majour causes of CKD are type 2 diabetic nephropathy, polycystic kidney disease and chronic glomerulonephritis. IgA nephropathy (IgAN) is the most common type of primary chronic glomerulonephritis.
Galactose-deficient IgA1 (Gd-IgA1) has been reported as a critical effector molecule in the pathogenesis and progression of IgAN.
17th International Symposium
on IgA Nephropathy
28–30 September 2023 in TOKYO
17the International Symposium on IgA Nephropathy was held in Tokyo on 28-30 September. We exhibited and our KM55 related products attracted a lot of attention.
Learn More about KM55
| ELISA | |
|---|---|
| #27600 Gd-IgA1 Assay Kit - IBL | |
| ・Sample | : Serum, EDTA plasma, Urine |
| ・Measurement range | : 1.56 ～ 100 ng/mL |
| ・Sensitivity | : 0.488 ng/mL |
| ・Total Time | : Approx. 2.5hr |
| KM55 | |
| #10777 Anti-Human Gd-IgA1(KM55) Rat IgG MoAb | |
| ・Application | : IHC |
| ・Species | : Human |
| ・Package size | : 10µg, 100µg |
| IHC Protocol | |
| References: references｜Immuno-Biological Laboratories Co,Ltd.｜IBL (ibl-japan.co.jp) | |
| *For research use only, not for use in diagnostic procedures. | |
| KM55 MoAb | ||
|---|---|---|
 |
 |
 |
| Anti-IgA | ||
 |
 |
 |
Please feel free to contact us.
Sales Department
Antibody related Business Division
Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp
